Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Renata Zelic, Francesca Giunchi, Jonna Fridfeldt, Jessica Carlsson, Sabina Davidsson, Luca Lianas, Cecilia Mascia, Daniela Zugna, Luca Molinaro, Per Henrik Vincent, Gianluigi Zanetti, Ove Andrén, Lorenzo Richiardi, Olof Akre, Michelangelo Fiorentino & Andreas Pettersson. (2022) Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. Clinical Epidemiology 14, pages 59-70.
Read now
Read now
Elin Axén, Johan Stranne, Marianne Månsson, Erik Holmberg & Rebecka Arnsrud Godtman. (2022) Biochemical recurrence after radical prostatectomy – a large, comprehensive, population-based study with long follow-up. Scandinavian Journal of Urology 56:4, pages 287-292.
Read now
Read now
Giuseppe Fallara, Fredrik Sandin, Johan Styrke, Stefan Carlsson, Ingela Franck Lissbrant, Johan Ahlgren, Ola Bratt, Mats Lambe & Pär Stattin. (2021) Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic. Scandinavian Journal of Urology 55:3, pages 184-191.
Read now
Read now
Johanna Svensson, Ingela Franck Lissbrant, Oskar Gauffin, Marie Hjälm-Eriksson, Suzanne Kilany, Karin Fagerlund & Pär Stattin. (2021) Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scandinavian Journal of Urology 55:1, pages 1-8.
Read now
Read now
Kerri Beckmann, Hans Garmo, Per Nilsson, Ingela Franck Lissbrant, Anders Widmark & Pär Stattin. (2020) Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998–2016. Acta Oncologica 59:5, pages 549-557.
Read now
Read now
Marcus Westerberg, Ingela Franck Lissbrant, Jan Erik Damber, David Robinson, Hans Garmo & Pär Stattin. (2020) Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta Oncologica 59:1, pages 106-111.
Read now
Read now
Frederik Birkebæk Thomsen, Cecilia Bosco, Hans Garmo, Jan Adolfsson, Niklas Hammar, Pär Stattin & Mieke Van Hemelrijck. (2019) Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta Oncologica 58:1, pages 110-118.
Read now
Read now
Hampus Nugin, Yasin Folkvaljon, Jan-Erik Damber, Jan Adolfsson, David Robinson & Pär Stattin. (2018) Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scandinavian Journal of Urology 52:4, pages 277-284.
Read now
Read now
Ingela Franck Lissbrant, Eugenio Ventimiglia, David Robinson, Magnus Törnblom, Marie Hjälm-Eriksson, Mats Lambe, Yasin Folkvaljon & Pär Stattin. (2018) Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scandinavian Journal of Urology 52:2, pages 143-150.
Read now
Read now
Katarina Tomic, Marcus Westerberg, David Robinson, Hans Garmo & Pär Stattin. (2016) Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. Acta Oncologica 55:12, pages 1461-1466.
Read now
Read now
Jón Ö. Fridriksson, Yasin Folkvaljon, Per Nilsson, David Robinson, Ingela Franck-Lissbrant, Behfar Ehdaie, James A. Eastham, Anders Widmark, Camilla T. Karlsson & Pär Stattin. (2016) Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study. Scandinavian Journal of Urology 50:5, pages 338-345.
Read now
Read now
Karl-Johan Lundström, Yasin Folkvaljon, Stacy Loeb, Anna Bill Axelson, Pär Stattin & Pär Nordin. (2016) Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy. Scandinavian Journal of Urology 50:3, pages 155-159.
Read now
Read now
Pär Stattin, Fredrik Sandin, Torsten Sandbäck, Jan-Erik Damber, Ingela Franck Lissbrant, David Robinson, Ola Bratt & Mats Lambe. (2016) Dashboard report on performance on select quality indicators to cancer care providers. Scandinavian Journal of Urology 50:1, pages 21-28.
Read now
Read now
Articles from other publishers (40)
Casey Crump, Pär Stattin, James D Brooks, Jan Sundquist, Alexis C Edwards, Weiva Sieh & Kristina Sundquist. (2023) Risks of alcohol and drug use disorders in prostate cancer survivors: a national cohort study. JNCI Cancer Spectrum 7:4.
Crossref
Crossref
Richard Shore, Ji Zhang, Weimin Ye, Pär Stattin & Mats Lindblad. (2023) Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study. Cancer Causes & Control.
Crossref
Crossref
Andri Wilberg Orrason, Johan Styrke, Hans Garmo & Pär Stattin. (2022) Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU International 131:4, pages 486-493.
Crossref
Crossref
Andri Wilberg Orrason, Marcus Westerberg, Peter Albertsen, Johan Styrke, David Robinson, Hans Garmo & Pär Stattin. (2022) Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy. PLOS ONE 17:11, pages e0277784.
Crossref
Crossref
Magdalena Lycken, Oskar Bergengren, Linda Drevin, Hans Garmo, Marcus Westerberg, Elin Axén, Johan Stranne, Lars Holmberg & Anna Bill-Axelson. (2022) Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths. European Urology Open Science 41, pages 81-87.
Crossref
Crossref
Johan Björklund, Pär Stattin, Erik Rönmark, Markus Aly & Olof Akre. (2021) The 90‐day cause‐specific mortality after radical prostatectomy: a nationwide population‐based study. BJU International 129:3, pages 318-324.
Crossref
Crossref
Rolf Gedeborg, Johan Styrke, Stacy Loeb, Hans Garmo & Pär Stattin. (2021) Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLOS ONE 16:10, pages e0255966.
Crossref
Crossref
Andri Wilberg Orrason, Hans Garmo, Johan Styrke, Paul W Dickman & Pär Stattin. (2021) Comparison of Relative Survival and Cause-Specific Survival in Men With Prostate Cancer According to Age and Risk Category: A Nationwide, Population-Based Study. American Journal of Epidemiology 190:10, pages 2053-2063.
Crossref
Crossref
Frederik B. Thomsen, Hans Garmo, Klaus Brasso, Lars Egevad & Pär Stattin. (2021) Temporal changes in cause‐specific death in men with localised prostate cancer treated with radical prostatectomy: a population‐based, nationwide study. Journal of Surgical Oncology 124:5, pages 867-875.
Crossref
Crossref
Richard Shore, Jingru Yu, Weimin Ye, Jesper Lagergren, Martin Rutegård, Olof Akre, Pär Stattin & Mats Lindblad. (2021) Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. Scientific Reports 11:1.
Crossref
Crossref
Marcus Westerberg, Rolf Larsson, Lars Holmberg, Pär Stattin & Hans Garmo. (2020) Simulation model of disease incidence driven by diagnostic activity. Statistics in Medicine 40:5, pages 1172-1188.
Crossref
Crossref
Kerri Beckmann, Hans Garmo, Ingela Franck Lissbrant & Pär Stattin. (2021) The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries. Cancers 13:4, pages 875.
Crossref
Crossref
David Thurtle, Ola Bratt, Pär Stattin, Paul Pharoah & Vincent Gnanapragasam. (2020) Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). BMC Medicine 18:1.
Crossref
Crossref
Zdravko P Vassilev, Montse Soriano Gabarró, James A Kaye, Catherine W Saltus, Oliver Riedel, Oliver Scholle, Juha Mehtälä, Pasi Korhonen, Edeltraut Garbe & Jihong Zong. (2020) Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. Future Oncology 16:25, pages 1889-1901.
Crossref
Crossref
Kerri Beckmann, Hans Garmo, Bertil Lindahl, Lars Holmberg, Pär Stattin, Jan Adolfsson, J. Kennedy Cruickshank & Mieke Van Hemelrijck. (2020) Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer and Prostatic Diseases 23:3, pages 527-533.
Crossref
Crossref
Andri Wilberg Orrason, Marcus Westerberg, Hans Garmo, Ingela Franck Lissbrant, David Robinson & Pär Stattin. (2020) Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population‐based study in Sweden. BJU International 126:1, pages 142-151.
Crossref
Crossref
Ola Bratt, Linda Drevin, Karl-Göran Prütz, Stefan Carlsson, Lars Wennberg & Pär Stattin. (2020) Prostate cancer in kidney transplant recipients - a nationwide register study. BJU International 125:5, pages 679-685.
Crossref
Crossref
Anna Plym, Mark Clements, Margaretha Voss, Lars Holmberg, Pär Stattin & Mats Lambe. (2020) Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study. BMJ Open 10:3, pages e032914.
Crossref
Crossref
Renata Zelic, Hans Garmo, Daniela Zugna, Pär Stattin, Lorenzo Richiardi, Olof Akre & Andreas Pettersson. (2020) Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. European Urology 77:2, pages 180-188.
Crossref
Crossref
Frederik B. Thomsen, Marcus Westerberg, Hans Garmo, David Robinson, Lars Holmberg, Hans David Ulmert & Pär Stattin. (2020) Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. PLOS ONE 15:1, pages e0228447.
Crossref
Crossref
Vincent J. Gnanapragasam, Tristan Barrett, Vineetha Thankapannair, David Thurtle, Jose Rubio-Briones, Jose Domínguez-Escrig, Ola Bratt, Par Statin, Kenneth Muir & Artitaya Lophatananon. (2019) Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer. BJU International 124:5, pages 758-767.
Crossref
Crossref
Markus Aly, Mark Clements, Caroline E. Weibull, Tobias Nordström, Erik Näslund, Jan Adolfsson & Henrik Grönberg. (2019) Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study. European Urology Focus 5:5, pages 842-848.
Crossref
Crossref
Renata Zelic, Daniela Zugna, Matteo Bottai, Ove Andrén, Jonna Fridfeldt, Jessica Carlsson, Sabina Davidsson, Valentina Fiano, Michelangelo Fiorentino, Francesca Giunchi, Chiara Grasso, Luca Lianas, Cecilia Mascia, Luca Molinaro, Gianluigi Zanetti, Lorenzo Richiardi, Andreas Pettersson & Olof Akre. (2019) Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study. American Journal of Epidemiology 188:6, pages 1165-1173.
Crossref
Crossref
Walter Cazzaniga, Hans Garmo, David Robinson, Lars Holmberg, Anna Bill-Axelson & Pär Stattin. (2019) Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study. BJU International 123:3, pages 421-428.
Crossref
Crossref
Katarina Tomic, Eugenio Ventimiglia, David Robinson, Christel Häggström, Mats Lambe & Pär Stattin. (2018) Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. International Journal of Cancer 142:12, pages 2478-2484.
Crossref
Crossref
David Robinson, Hans Garmo, Ingela Franck Lissbrant, Anders Widmark, Andreas Pettersson, Adalsteinn Gunnlaugsson, Jan Adolfsson, Ola Bratt, Per Nilsson & Pär Stattin. (2018) Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. European Urology 73:4, pages 502-511.
Crossref
Crossref
Eugenio Ventimiglia, Yasin Folkvaljon, Stefan Carlsson, Ola Bratt, Francesco Montorsi, Daniela Volz, Olof Akre, Eva Johansson & Pär Stattin. (2018) Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery. Journal of Surgical Oncology 117:2, pages 321-327.
Crossref
Crossref
Frederik Birkebæk Thomsen, Fredrik Sandin, Hans Garmo, Ingela Franck Lissbrant, Göran Ahlgren, Mieke Van Hemelrijck, Jan Adolfsson, David Robinson & Pär Stattin. (2017) Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. European Urology 72:6, pages 920-928.
Crossref
Crossref
Jón Örn Fridriksson, Yasin Folkvaljon, Karl-Johan Lundström, David Robinson, Stefan Carlsson & Pär Stattin. (2017) Long-term adverse effects after retropubic and robot-assisted radical prostatectomy. Nationwide, population-based study. Journal of Surgical Oncology 116:4, pages 500-506.
Crossref
Crossref
Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, Hans Garmo, David Robinson, Ingela Franck Lissbrant, Håkan Jonsson & Ola Bratt. (2017) Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. European Urology 72:1, pages 125-134.
Crossref
Crossref
Stacy LoebYasin FolkvaljonJan-Erik DamberJoseph AlukalMats LambePär Stattin. (2017) Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. Journal of Clinical Oncology 35:13, pages 1430-1436.
Crossref
Crossref
Mary K. Downer, Julie L. Batista, Lorelei A. Mucci, Meir J. Stampfer, Mara Meyer Epstein, Niclas Håkansson, Alicja Wolk, Jan-Erik Johansson, Ove Andrén, Katja Fall & Sven-Olof Andersson. (2017) Dairy intake in relation to prostate cancer survival. International Journal of Cancer 140:9, pages 2060-2069.
Crossref
Crossref
Pär Stattin, Fredrik Sandin, Karin Hellström, David Robinson & Ingela Franck Lissbrant. (2017) The National Prostate Cancer Register of Sweden. Tijdschrift voor Urologie 7:2-3, pages 50-59.
Crossref
Crossref
Andreas Thorstenson, Hans Garmo, Jan Adolfsson & Ola Bratt. (2017) Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study. Journal of Urology 197:1, pages 61-66.
Crossref
Crossref
Frederik B. Thomsen, Yasin Folkvaljon, Klaus Brasso, Stacy Loeb, David Robinson, Lars Egevad & Pär Stattin. (2016) Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. Journal of Surgical Oncology 114:6, pages 664-670.
Crossref
Crossref
Ola Bratt, Linda Drevin, Olof Akre, Hans Garmo & Pär Stattin. (2016) Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. Journal of the National Cancer Institute 108:10, pages djw110.
Crossref
Crossref
Johan Björklund, Yasin Folkvaljon, Alexander Cole, Stefan Carlsson, David Robinson, Stacy Loeb, Pär Stattin & Olof Akre. (2016) Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population-based study. BJU International 118:2, pages 302-306.
Crossref
Crossref
Anna Plym, Flaminia Chiesa, Margaretha Voss, Lars Holmberg, Eva Johansson, Pär Stattin & Mats Lambe. (2016) Work Disability After Robot-assisted or Open Radical Prostatectomy: A Nationwide, Population-based Study. European Urology 70:1, pages 64-71.
Crossref
Crossref
Frederik B. Thomsen, Yasin Folkvaljon, Hans Garmo, David Robinson, Stacy Loeb, Christian Ingvar, Mats Lambe & Pär Stattin. (2016) Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. International Journal of Cancer 138:9, pages 2154-2160.
Crossref
Crossref
Ola Bratt, Yasin Folkvaljon, Marie Hjälm Eriksson, Olof Akre, Stefan Carlsson, Linda Drevin, Ingela Franck Lissbrant, Danil Makarov, Stacy Loeb & Pär Stattin. (2015) Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. European Urology 68:1, pages 53-58.
Crossref
Crossref